Iraq
Tuberculosis profile
Population  2013 34 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.78 (0.016–3) 2.3 (0.05–8.8)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 25 (12–44) 75 (35–129)
Incidence  (includes HIV+TB) 15 (13–17) 45 (39–50)
Incidence (HIV+TB only)        
Case detection, all forms (%) 57 (50–65)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 3.7 (2.5–4.9) 20 (13–27)
MDR-TB cases among notified pulmonary
TB cases
180 (120–240) 130 (85–170)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 2 738   302
Pulmonary, clinically diagnosed 2 240    
Extrapulmonary 3 274    
       
Total new and relapse 8 554    
Previously treated, excluding relapses 329    
Total cases notified 8 883    
Among 8 554 new and relapse cases:
671 (8%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 3 241 (118%) 382 (61%) 3 623
Laboratory-confirmed RR-/MDR-TB cases     167
Patients started on MDR-TB treatment     84
TB/HIV 2013 Number (%)
TB patients with known HIV status 3 017 (34)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 91
Previously treated cases, excluding relapse, registered in 2012 81
HIV-positive TB cases, all types, registered in 2012 50
RR-/MDR-TB cases started on second-line treatment in 2011 64
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 1.2
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 13
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 27
% Funded domestically 88%
% Funded internationally 8%
% Unfunded 4%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-30 Data: www.who.int/tb/data